Clinical Trials Sponsored by Arcadia University

Total 219883 results

Arcadia University

Completed

Non-invasive Brain Stimulation to Improve Quadriceps Muscle Function After Anterior Cruciate Ligament Reconstruction

Anterior Cruciate Ligament Reconstruction | Transcranial Direct Current Stimulation | Quadriceps Muscle Weakness

United States
Arcadia University

Completed

Effect of Leg Strengthening Exercise After Hip Fracture

Hip Fractures

United States
Acadia University

Unknown

Probiotics and the Microbiome: Clinical Intervention Trial for Anxiety and Depression

Depression | Anxiety

Canada
University of Colorado, Denver
Arcadia University

Completed

Improving Function, Participation and Function After Acute Hospitalization in Older Adults

Frail Older Adults

United States
ACADIA Pharmaceuticals Inc.

Recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Hungary, Poland, Italy
ACADIA Pharmaceuticals Inc.

Completed

Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Completed

Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Serbia, United States, Poland, Georgia, Russian Federation, Bulgaria, Colombia, Czechia, Mexico, Romania, South Africa, Ukraine
ACADIA Pharmaceuticals Inc.

Completed

Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy

Acute Postoperative Pain | Bunionectomy

United States
ACADIA Pharmaceuticals Inc.

Terminated

Evaluate the Efficacy and Safety of ACP-044 in Subjects With Pain Associated With Osteoarthritis of the Knee

Osteoarthritis Pain

United States
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis

United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

Spain, United States, Belgium, Austria, Serbia, Poland, Portugal, Italy, Sweden
ACADIA Pharmaceuticals Inc.

Approved for marketing

Expanded Access of Pimavanserin for Patients With PD Psychosis

Parkinson's Disease Psychosis
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

United States, Canada
ACADIA Pharmaceuticals Inc.

Not yet recruiting

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Alzheimer's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia

Schizophrenia

Lithuania, Canada, Ukraine, Argentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Poland, Russian Federation, Serbia, Spain, United States
ACADIA Pharmaceuticals Inc.

Completed

An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett Syndrome (DAFFODIL™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
ACADIA Pharmaceuticals Inc.

Completed

An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients

Parkinson's Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Treatment of Depression in Adults With Parkinson's Disease (PD)

United States
ACADIA Pharmaceuticals Inc.

Completed

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

Schizophrenia

United States, Russian Federation, Hungary, Bulgaria, Serbia, Ukraine, Lithuania, Canada, Czechia, Poland
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

United States, Austria, France, Canada, Belgium, Russian Federation, Serbia, Ukraine, Poland, Portugal, Italy, India, United Kingdom, Sweden
ACADIA Pharmaceuticals Inc.

Completed

Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone

Schizophrenia

United States, Brazil
ACADIA Pharmaceuticals Inc.

Completed

Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug

Parkinson's Disease | Hallucinations | Psychoses

United States
ACADIA Pharmaceuticals Inc.

Recruiting

Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Hyperphagia in Prader-Willi Syndrome

United States, Canada
ACADIA Pharmaceuticals Inc.

Recruiting

Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder

Irritability Associated With Autism Spectrum Disorder

United States, Spain, France, Australia, Poland, Italy, Hungary
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LILAC™)

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Active, not recruiting

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2)

Schizophrenia

Argentina, Bulgaria, Croatia, Czechia, Hungary, Italy, Lithuania, Poland, Russian Federation, Serbia, Spain, Ukraine
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Extension Study of Trofinetide for Rett Syndrome

Rett Syndrome

United States
ACADIA Pharmaceuticals Inc.

Completed

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

Parkinson Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Neuropsychiatric Symptoms Related to Neurodegenerative Disease

United States, Russian Federation, Serbia, Poland, Georgia, Czechia, Bulgaria, Colombia, Mexico, Romania, South Africa, Ukraine
ACADIA Pharmaceuticals Inc.

Terminated

Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine

Parkinson's Disease

United States
ACADIA Pharmaceuticals Inc.

Terminated

The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) Study

Parkinson Disease Psychosis

United States
ACADIA Pharmaceuticals Inc.

Completed

Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis

Dementia-related Psychosis

United States, Spain, Poland, Ukraine, Chile, Czechia, United Kingdom, Bulgaria, France, Germany, Italy, Serbia, Slovakia
ACADIA Pharmaceuticals Inc.

Completed

Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)

Schizophrenia

United States, Spain, Hungary, Bulgaria, Russian Federation, Serbia, Ukraine, Poland, Canada, Czechia
ACADIA Pharmaceuticals Inc.

Completed

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Agitation and Aggression in Alzheimer's Disease

United States, Spain, Chile, France, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)

Adjunctive Treatment of Major Depressive Disorder

United States
ACADIA Pharmaceuticals Inc.

Terminated

Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Agitation and Aggression in Alzheimer's Disease (SERENE)

Agitation and Aggression in Alzheimer's Disease

United States, France, Spain, Chile, United Kingdom
ACADIA Pharmaceuticals Inc.

Completed

A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis

Parkinson's Disease Psychosis

France, United States, Bulgaria, Russian Federation, United Kingdom, Ukraine, India
ACADIA Pharmaceuticals Inc.

Completed

ACP-104 in Acutely Psychotic Subjects With Schizophrenia

Schizophrenia

United States
Acadia University
Lallemand Health Solutions

Unknown

Effects of a Probiotic Supplement on Symptoms of Attention Deficit Hyperactivity Disorder and Anxiety in Children

Anxiety | Attention Deficit Hyperactivity Disorder

Canada
University of Rochester
ACADIA Pharmaceuticals Inc.

Completed

Characterization and Progression of Minor Phenomena in Parkinson's Disease (PD)

Parkinson Disease | Hallucinations | Parkinson Disease Psychosis | Delusion

United States
Ohio State University
ACADIA Pharmaceuticals Inc.

Not yet recruiting

Pimavanserin and Aggression and Social Cognition.

Intermittent Explosive Disorder

United States
Vanderbilt University Medical Center
ACADIA Pharmaceuticals Inc.

Recruiting

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Parkinson Disease | Neurodegenerative Diseases | Parkinson Disease Psychosis

United States
Acacia Pharma Ltd

Completed

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Renal Disease, End Stage

United States
Acacia Pharma Ltd

Completed

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

CINV

Denmark
Stem Cells Arabia

Unknown

Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy

Cerebral Palsy
Stem Cells Arabia

Unknown

Transplantation of Autologous Bone Marrow or Leukapheresis-Derived Stem Cells for Treatment of Spinal Cord Injury

Spinal Cord Injury

Jordan
Acacia Pharma Ltd

Completed

European Phase III Study of APD421 in PONV

PONV

France, Germany

Clinical Trials Sponsored by Arcadia University

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations